Population Pharmacokinetics and Immunogenicity of Adalimumab in Adult Patients with Moderate-to-Severe Hidradenitis Suppurativa
- 9 January 2017
- journal article
- research article
- Published by Springer Science and Business Media LLC in Clinical Pharmacokinetics
- Vol. 56 (9), 1091-1102
- https://doi.org/10.1007/s40262-016-0502-4
Abstract
Hidradenitis suppurativa (HS) is a serious, debilitating, chronic inflammatory skin disease. Adalimumab is a fully human, immunoglobulin G1 monoclonal antibody specific for tumor necrosis factor-alpha recently approved for use in patients with HS. The aim of this study is to describe the population pharmacokinetics and immunogenicity of adalimumab in adult patients with HS.Keywords
Funding Information
- AbbVie
This publication has 27 references indexed in Scilit:
- Incidence of Hidradenitis Suppurativa and Associated Factors: A Population-Based Study of Olmsted County, MinnesotaJournal of Investigative Dermatology, 2013
- The off-label treatment of severe hidradenitis suppurativa with TNF-α inhibitors: a systematic reviewJournal of Dermatological Treatment, 2012
- Increased Prevalence of Metabolic Syndrome in Patients with Acne InversaPLOS ONE, 2012
- Adalimumab Induces and Maintains Clinical Remission in Patients With Moderate-to-Severe Ulcerative ColitisGastroenterology, 2012
- Elevated levels of tumour necrosis factor (TNF)-α, interleukin (IL)-1β and IL-10 in hidradenitis suppurativa skin: a rationale for targeting TNF-α and IL-1βBritish Journal of Dermatology, 2011
- Hidradenitis suppurativa markedly decreases quality of life and professional activityJournal of the American Academy of Dermatology, 2010
- Population pharmacokinetic analysis of infliximab in patients with ulcerative colitisEuropean Journal of Clinical Pharmacology, 2009
- Hidradenitis suppurativa: A comprehensive reviewJournal of the American Academy of Dermatology, 2009
- Population Pharmacokinetic Modeling of Ustekinumab, a Human Monoclonal Antibody Targeting IL‐12/23p40, in Patients With Moderate to Severe Plaque PsoriasisThe Journal of Clinical Pharmacology, 2009
- Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trialJournal of the American Academy of Dermatology, 2007